Business Wire

Nanoco to Present at Upcoming Industry Conferences

18.2.2025 12:00:00 CET | Business Wire | Press release

Share

Nanoco Group PLC (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other advanced nanomaterials, is ramping up its commercial engagement as it transitions to scaled production. Over the coming months the company will be attending several key industry events to showcase its technology, connect with its customers and development partners, and to accelerate adoption of its solutions.

In March, Nanoco Founder and CTO Dr. Nigel Pickett will speak at the Society for Information Display (SID) UK Chapter meeting in London. His presentation, “Molecular Seeding Technology for Display Applications and Beyond,” will explain how Nanoco’s technology can enhance micro-LED and other displays, making them more efficient and cost-effective for mass production. As the industry moves toward brighter, more energy-efficient screens, Nanoco is working with partners to bring its technology into commercial products.

Later that month Nanoco will attend and sponsor Image Sensors Europe, a major industry gathering of over 250 vision technology professionals. The team will engage with potential customers and partners, highlighting how Nanoco’s quantum dot-based imaging solutions are unlocking new possibilities across several industries.

In April, Nanoco will be presenting its latest results on Image Sensors at SPIE Defense + Commercial Sensing conference in Orlando, Florida. The presentation, “Molecular Seeding Technology: Enabling Sensing Applications of the Future,” will highlight how Nanoco’s technology enables the production of Quantum Dots at scale making high-performance infrared image sensors more affordable and available. These sensors are in growing demand and Nanoco is positioning itself as a key player in that industry.

Nigel Pickett, Ph.D., the founder and CTO of Nanoco, said:

"Molecular seeding technology is our foundational IP for high volume quantum dot production. It allows us to manufacture high-quality materials efficiently, meeting the strict demands of the electronics industry. We believe it is the only feasible method to manufacture Quantum Dots at scale. This technology has already played a pivotal role in advancing display technologies, and we are now seeing the same potential in quantum dot enabled sensing applications where Nanoco has the largest product portfolio.

Dmitry Shashkov, Ph.D., CEO of Nanoco, said:

"We are excited to present our latest achievements to the industry and take the next steps to align the business with commercial execution. These industry events are not just about presenting technology—they are about building relationships with partners and customers who will be instrumental in bringing QD Image Sensors into mass adoption. We at Nanoco see the next 1-2 years as a major inflection point for the industry, as low-cost, wafer-scale production processes will bring QD Image Sensors to a wide variety of applications, including consumer, automotive, industrial and defense sectors."

About Nanoco Group plc

Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium-free quantum dots (CFQD®) and other nanomaterials for use in the electronics industry. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build a world-class, patent-protected IP portfolio alongside its existing scaled-up production facilities for commercial orders.

For further information, please visit: www.nanocotechnologies.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218331567/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release

Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao​ Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit​ Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao.​ Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat

Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 08:49:00 CEST | Press release

IQM Radiance R1 is the first on-premises quantum computer for the PUT. The university aims to use the system to spearhead quantum education and research while boosting STEM in the country. This is the second operational quantum computer deployed in Poland by IQM. The university recognizes the significant long-term potential of integrating quantum computing, artificial intelligence, and high-performance computing (HPC), and intends to play a key role in shaping this transformation in Europe. Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weyde

BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 08:30:00 CEST | Press release

BearingPoint is expanding its AI portfolio with a fully owned, sovereign on-premise and edge infrastructure designed specifically for generative and agentic AI workloads in highly regulated industries and public administrations in Europe. Building on decades of experience operating its own sovereign cloud, the firm now offers clients both dedicated hardware and token-based access to large language models – fully GDPR-compliant, ISO-certified and, on request, NIS2- and DORA-ready BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical sc

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release

Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho

Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release

Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye